Elan reaffirms Tysabri commitment

Pharmaceutical company Elan has forecast a €150m-€175m full-year before-tax loss, excluding revenues from its suspended MS drug Tysabri.

Revenue for the first three months of the year was $134.3m (€106m), ahead of analysts' forecasts of $127.1m (€100m).